BBP
Virtus LifeSci Biotech Products ETF
The BioShares Biotechnology Products Fund seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index.
US
EQUITY
Rules-Based
MANAGEMENT STYLE
32.0 M
ASSETS UNDER MGMT
79 bp
EXPENSES
Fund Basics
| Fund sponsor | ETFis Capital LLC |
| Category | US |
| Asset class | Equity |
| Website | link... |
| Inception date | Dec 16, 2014 |
| Assets (mns) | $32 |
| Expense ratio | 79 bp |
| Currency | USD |
Sector Breakdown
Fund Structure
| Regulation | Open-End Investment Company |
| Distributions | Annually |
| Taxation | 1099 |
| Stock selection | Proprietary |
| Weighting | Equal |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
| INSMED INC | 3.3 % |
| BRIDGEBIO PHARMA, INC. | 3.2 % |
| ALNYLAM PHARMACEUTICALS INC | 3.0 % |
| RHYTHM PHARMACEUTICALS, INC. | 3.0 % |
| MIRUM PHARMACEUTICALS, INC. | 3.0 % |
| BEIGENE LTD. SPONSORED ADR | 2.9 % |
| IONIS PHARMACEUTICALS, INC. | 2.7 % |
| INTRA-CELLULAR THERAPIES INC | 2.6 % |
| ASCENDIS PHARMA A/S | 2.6 % |
| HALOZYME THERAPEUTICS INC | 2.6 % |
Constituent Breakdown
| Number of holdings | 57 |
| Herfindahl-Hirschman Index | 245 |
| Wgt avg mkt cap (mns) | $18,157 |
| Large cap (>$10bn) | 40.0% |
| Mid cap ($2-10bn) | 45.3% |
| Small cap (<$2bn) | 29.2% |
| Developed mkts. | 109.8% |
| Emerging mkts. | 4.8% |
Country Exposure
 |
UNITED STATES | 95.4 % |
 |
CHINA | 4.8 % |
 |
BRITAIN | 3.8 % |
 |
DENMARK | 2.6 % |
 |
CAYMAN ISLANDS | 2.3 % |
 |
CANADA | 2.1 % |
 |
SWITZERLAND | 2.0 % |
 |
GERMANY | 1.5 % |
Historical Performance
Standardized Performance (as of 10/31/2025)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 24.3% | 17.9% | 26.5% | 16.9% | 9.2% | 9.3% | -- | 10.2% |
| Dividend Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | -- | 0.2% |
| Total Returns | 24.3% | 17.9% | 26.5% | 16.9% | 9.2% | 9.5% | -- | 10.3% | Ann. Volatility | 25.8% | 25.8% | 24.2% | 23.8% | 26.2% | 28.0% | -- | 28.1% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.98 | 48% |
| MSCI EAFE | 0.74 | 36% |
| MSCI Emg Mkts | 0.53 | 21% |
Liquidity Measures
| Avg. volume (000) | 4 |
| ADV traded (mns) | $0 |
| Turnover | 1.0% |
| Avg. Bid/Ask (% of price) | 0.27% |
Technical Indicators
| 30d moving avg. (EMA) | $74.47 |
| Relative strength (RSI) | 60 |
| MACD/Signal | 1.25/1.31 |
| Bollinger Bands (Upper/Lower) | $78.58/$71.99 |
| Short interest (% of AUM) | 0.2% |
Distributions
Assets Under Management (mns)
Money Flows (mns)
Short Interest (as % of shares outstanding)
Long Money Flows (mns)
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. BBP |
Expenses vs. BBP |
ALTAR Score™ vs. BBP |
|---|---|---|---|---|
| XBI | State Street SPDR S&P Biotech ETF | 45.6% | -44 bp | -2.0% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 36.4% | -60 bp | +0.3% |
| IBB | iShares Biotechnology ETF | 35.2% | -34 bp | -0.1% |
| PBE | Invesco Biotechnology & Genome ETF | 31.8% | -21 bp | +1.5% |
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 31.7% | -23 bp | +2.8% |
| WDNA | WisdomTree BioRevolution Fund | 27.7% | -34 bp | -2.2% |
| BBH | VanEck Biotech ETF | 26.7% | -44 bp | +5.1% |
| HELX | Franklin Genomic Advancements ETF | 25.0% | -29 bp | -0.4% |
| SBIO | ALPS Medical Breakthroughs ETF | 23.3% | -29 bp | 0.0% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 23.2% | -19 bp | +8.0% |
Risk and Returns: BBP vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Book value per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2024 | 2025 | 2026 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 11/28/2025
Peer Group Comparison Sample data. Subscribe for access.
Price-to-Earnings
Price-to-Sales
Price-to-Book Value
Price-to-Cash Flow
Price-to-Growth
Dividend Yield
Historical Valuation Trends Sample data. Subscribe for access.
SHOWING:
Price-to-Earnings
Price-to-Earnings
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
AVOID
Not worthwhile for most investors. A rating of AVOID is assigned to ETFs with ALTAR Scores in the lowest quintile (the bottom 20%) of their category. Often, funds in this category consist of stocks with little if any history or expectation of profitability, and as a result our fundamentally-driven analysis may be less relevant.
ALTAR Score™
BBP
-1.6%
Cat. Avg
5.6%
ALTAR Score™ Calculation
Category Overview
There are 1012 funds in the US Equity category, with an average ALTAR Score™
of 5.6% and a standard deviation of
2.3%. BBP's ALTAR Score™ is approximately
3.1 standard deviations
below
the category average. This places BBP in the 1st percentile among funds in the category.
Sell Side Consensus Rating
Sell-side recommendations on the ETF's individual constituents
BBPSELL
U/W
HOLD
O/W
BUY